Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Addressing dyslipidemic risk beyond LDL-cholesterol.

The Journal of clinical investigation - 4 Jan 2022

Tall Alan R, Thomas David G, Gonzalez-Cabodevilla Ainara G, Goldberg Ira J

Abstract excerpt

Despite the success of LDL-lowering drugs in reducing cardiovascular disease (CVD), there remains a large burden of residual disease due in part to persistent dyslipidemia characterized by elevated levels of triglyceride-rich lipoproteins (TRLs) and reduced levels of HDL. This form of dyslipidemia is increasing globally as a result of the rising prevalence of obesity and metabolic syndrome. Accumulating evidence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-Like Protein 3
Share to Apolipoprotein C-III
Share to Atherosclerosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Dyslipidemias

Share to Foam Cells

Share to Lipoproteins, HDL

Share to Metabolic Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 34981790
DOI: 10.1172/JCI148559
PMCID: PMC8718149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Addressing dyslipidemic risk beyond LDL-cholesterol.PMID 34981790Read ↗

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.Semantic proximity Read ↗

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction.Semantic proximity Read ↗

Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.Semantic proximity Read ↗

Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.Semantic proximity Read ↗

Non-HDL cholesterol as a therapeutic goal.Semantic proximity Read ↗

New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.Semantic proximity Read ↗

Demystifying the management of hypertriglyceridaemia.Semantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

Novel and future lipid-modulating therapies for the prevention of cardiovascular diseaseSemantic proximity Read ↗

Updates in Small Interfering RNA for the Treatment of DyslipidemiasSemantic proximity Read ↗

Hyperlipidemia as a risk factor for cardiovascular disease.Semantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.